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Abstract
Objectives: Treatment of epistaxis in patients on anticoagulants is challenging and
associated with higher admission rates and longer hospital stays compared with
patients without anticoagulation. However, there is little information about epistaxis
in patients taking new direct oral anticoagulants such as rivaroxaban compared with
patients on traditional vitamin K antagonists such as phenprocoumon.
Design: Retrospective cohort study.
Setting: The study was conducted at the emergency department of the University
Hospital Inselspital, Bern, Switzerland.
Participants: All admissions to the emergency department of the University Hospital
Inselspital, Bern, Switzerland from 1st July 2012 to 30th June 2016 with non-traumatic
epistaxis on anticoagulant therapy with phenprocoumon or rivaroxaban were included.
Main outcome measures: We compared clinical outcome parameters (admission
rates, length of hospital stay and mortality) for both anticoagulant groups.
Results: We included 440 patients with epistaxis, 123 (28%) on rivaroxaban and
317 (72%) on phenprocoumon. Fewer hospital admissions and shorter hospital stays
were found in patients under rivaroxaban (12 (10.4%) vs 57 (18.0%) patients,
P=.033; 0.72.2 vs 1.53.7 days, P=.011) compared with phenprocoumon. Anterior
epistaxis was more common in the rivaroxaban group in contrast to posterior epis-
taxis in patients on phenprocoumon (74 (60.2%) vs 139 (43.8%) patients, P=.002; 7
(5.7%) vs 39 (12.3%) patients, P=.042).
Conclusions: Our data suggests that epistaxis on direct oral anticoagulation with
rivaroxaban is associated with shorter hospital stays and fewer hospital admissions
than epistaxis on vitamin K antagonist phenprocoumon.
1 | INTRODUCTION
Epistaxis is a common reason for emergency department (ED) atten-
dance, accounting for up to 1 in 200 ED visits in the United States.1
With 20,000 hospital admissions and 36 000 hospital bed days from
2014 to 2105 in the United Kingdom, epistaxis represents a relevant
burden to a medical system.2 Antithrombotic therapy was previously
found to be present in 60% of patients admitted to an ED with epis-
taxis.2 Specifically, epistaxis under anticoagulant therapy with the
vitamin K antagonist (VKA) warfarin is known to be associated with
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an increased hospital admission rate and length of hospital stay as
well as more surgical interventions compared with patients without
anticoagulant therapy.2,3
Current guidelines on anticoagulant treatment in venous throm-
boembolism and atrial fibrillation recommend new direct oral antico-
agulants (DOACs) over traditional anticoagulation treatment with
VKAs..4,5 As such it seems likely that patients taking DOACs will
become increasingly common in the ED. However, a recent review
of epistaxis patients found a lack of studies including patients trea-
ted with DOAC and could not identify a direct comparison of
patients under DOAC or VKAs.2 Only a few case reports about the
management of patients with epistaxis on DOAC therapy exist.6,7
Although severe bleeding complications in DOAC patients are rare,
epistaxis was found to be one of the most frequent minor bleeding
complication in patients on DOAC therapy.8
To our knowledge, no study has yet described the characteristics of
ED patients with epistaxis during DOAC therapy, nor did we find a direct
comparison of DOACs and VKAs in patients presenting with epistaxis.
Our study seeks to describe the characteristics of ED patients
with epistaxis treated with rivaroxaban compared to those with
phenprocoumon.
Additionally this study aims to identify differences in outcome
(admission rate, length of hospital stay and mortality) associated with
the two different types of anticoagulant therapy in this population.
2 | METHODS
2.1 | Ethical considerations
This retrospective cohort study is registered with the ethics commit-
tee of the Canton Bern, Switzerland (Number 073/2015).The
responsible ethics committee of the Canton Bern, Switzerland
waived the need for informed consent because of the sole use of
anonymised data collected during routine patient care.
2.2 | Study design
The study population included all admissions to the emergency
department (ED) of the University Hospital Inselspital, Bern,
Switzerland from 1st July 2012 to 30th June 2016. The ED has a
catchment area of about 2 million people in the Canton Bern,
Switzerland and treats about 40 000 patients per year.9
To include all anticoagulant patients older than 18 years of age
who were treated for epistaxis, a full-text search in the emergency
department information system (E.care, Turnhout, Belgium) was per-
formed for the medications “phenprocoumon” and “rivaroxaban” and
then screened for the keywords “epistaxis” or “nosebleed” and varia-
tions in spelling. Because diagnoses and procedures are documented
in free text in our ED and ICD or OPCS codes are generated only
afterwards for billing purposes, free text arguably reflects the medi-
cal conditions and necessities more closely and free of economic
considerations. As rivaroxaban is by far the DOAC with the highest
prevalence in our emergency patient population, our investigation
focused on patients taking this DOAC. Similarly phenprocoumon is
the coumarin most commonly prescribed in our catchment area.
Patient without documented anticoagulant therapy or those without
epistaxis at the time of admission were excluded (Figure 1). We fur-
ther excluded all trauma patients due to the different mechanism of
epistaxis in this population.
2.3 | Variables
We collected demographic data (age, gender, nationality), patient
outcome data (hospital admission, length of hospital stay, ED- and
in-hospital mortality), medical data (indication for anticoagulant ther-
apy, additional platelet-anticoagulation therapy, blood pressure),
specific factors concerning epistaxis (location of bleeding, ED
F IGURE 1 Flow chart
Keypoints
• Epistaxis is a common reason for emergency department
attendance and a relevant burden to a medical system.
• Epistaxis on direct oral anticaogulation with rivaroxaban
is associated with shorter hospital stays and fewer hospi-
tal admissions than epistaxis on vitamin K antagonist
phenprocoumon.
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therapy, need for blood transfusion) and laboratory results at admis-
sion (creatinine, international normalised ratio (INR), haemoglobin
(Hb), thrombocytes). In our university, ED patients with epistaxis are
treated by otolaryngologists. Thus, for the majority of patients the
location of bleeding could be detected by nasal endoscopy and doc-
umented in the medical records.
2.4 | Statistical analysis
Statistical analysis was performed in SPSS Statistics version 22
(IBM Zurich, Switzerland) with statistical significance defined as a
P-value <.05.
Descriptive statistics were used to describe patient’s baseline
characteristics. Patient demographic data, administrative data, medical
data and laboratory results were compared using Mann-Whitney U,
Pearson’s chi-squared and Fisher’s exact test, as applicable.
3 | RESULTS
The database search of about 160 000 ED admissions total during
4 years returned 3778 patients on DOAC anticoagulant therapy with
rivaroxaban and 6779 patients on VKA therapy with phenpro-
coumon (see Figure 1). These included 440 epistaxis patients of
which 123 patients were on DOAC therapy (28%) and 317 patients
on VKA (78%).
The demographic characteristics of both groups are summarised
in Table 1. Groups were found to be comparable regarding age
(75.811.2 years [DOAC] vs 75.211.7 years [VKA]; P=.727) and
gender (78 male DOAC patients (63%) vs 196 male VKA patients
(62%); P=.758). There was no significant difference in the indications
for anticoagulation therapy between the DOAC and VKA group
apart from the group of patients with mechanical heart valves, for
which the use of DOACs is currently not approved (0 patients (%) vs
21 patients (7%); P=.003*). To assess whether or not differences
between groups were due to a higher target-INR in patient anticoag-
ulated for mechanical heart valves, we tested for differences in INR
between VKA patients with (INR mean 2.580.78) and without (INR
mean 2.630.88) mechanical heart valve and found no significant
difference (P=.818).
Additional platelet-aggregation-inhibitor therapy was docu-
mented in 23 (18.7%) patients with DOACs and 39 (12.3%) patients
with VKAs (P=.084). For details about antiplatelet medication see
Table 1. Vital signs and blood results of both groups at admission
are summarised and compared in Table 2.
Comparing the location of epistaxis as documented in transnasal
endoscopy, we found a larger proportion of anterior epistaxis in DOAC
patients. In contrast, more VKA patients presented with posterior epis-
taxis (anterior: 74 (60.2%) DOAC vs 139 (43.8%) VKA; P=.002*; poste-
rior: 7 (5.7%) DOAC vs 39 (12.3%) VKA, P=.042*). Regarding
emergency treatment, no significant difference was found (Table 2).
The comparison of outcome parameters revealed an increased
hospital admission rate in VKA patients with epistaxis (12 (10.4%)
DOAC vs 57 (18.0%) VKA, P=.033*).
Of those admitted, the length of hospital stay was significantly
shorter in epistaxis patients on DOACs in comparison with patients
on VKAs (0.72.2 days [DOAC] vs 1.53.7 days [VKA], P=.011*).
No patient died in the ED and there was no significant difference
regarding in-hospital mortality (one patient (0.8%) [DOAC] vs three
patients (0.9%) [VKA], P=1.000).
4 | DISCUSSION
4.1 | Synopsis of key findings
This retrospective cohort study demonstrates a significantly lower
hospital admission rate and a significantly reduced length of hospi-
tal stay in patients on rivaroxaban compared with those treated
with phenprocoumon. Furthermore, we found that anterior epis-
taxis in patients treated with the DOAC rivaroxaban is significantly
more likely than in patients with the VKA phenprocoumon. In con-
trast to this, the prevalence of posterior epistaxis was found to be
significantly higher in patients on phenprocoumon compared with
rivaroxaban.
4.2 | Characteristics of ED patients with epistaxis
on the DOAC rivaroxaban compared to patients with
epistaxis on the VKA phenprocoumon
The patient groups included in our analysis are similar in demo-
graphic characteristics. However, the sample age overall is older than
a previously published population of unselected patients with
TABLE 1 Baseline characteristics of the study cohort according to
type of anticoagulant (n=440)
Characteristics
Rivaroxaban
n=123 (28%)
Phenprocoumon
n=317 (78%) P-value
Patient data
Age (y) 75.8  11.2 75.2  11.7 .727
Gender (male) 78 (63%) 196 (62%) .758
Nationality (Swiss) 113 (92%) 302 (95%) .167
Indication for anticoagulant therapy(%)
Atrial fibrillation 55 (45) 120 (38) .187
Thromboembolic event 15 (12) 50 (16) .343
Post-surgery 2 (2) 11 (4) .530
Mechanic heart valve 0 (0) 21 (7) .003*
Not documented 50 (41) 122 (39) .676
Additional platelet-aggregation-inhibitor therapy(%)
Acetylsalicylate acid 16 (13.0) 25 (7.9) .097
Clopidogrel 5 (4.1) 5 (1.6) .151
Acetylsalicylate acid
and clopidogrel
1 (0.8) 9 (2.8) .296
Prasugrel 1 (0.8) 0 (0) .280
Mean standard deviation or percentage (%) as appropriate, Mann-Whitney
U, Pearson’s Chi-Square or Fisher’s exact test as applicable. *P<.05.
SAUTER ET AL. | 3
epistaxis in general.10 This older age of epistaxis patients on antico-
agulant therapy is consistent with the findings of Smith et al.3 The
main indication for anticoagulation in our study was atrial fibrillation
(regardless of which anticoagulant was used). Increasing prevalence
of atrial fibrillation with older age may explain the relatively older
age of our population.
Laboratory results at admission were similar in both groups,
apart from the INR. This is not surprising, given the fact that
rivaroxaban has no linear effect on the INR and cannot be moni-
tored using the INR. Nevertheless, the low INR values documented
in patients with prescribed rivaroxaban are interesting, given the
fact that normally INR raises 2-12 hours after rivaroxaban intake.
With our retrospective data it remains unclear if patients on rivarox-
aban were undertreated or if the time point of rivaroxaban intake
was too long before ED admission. Therefore, further prospective
investigations including rivaroxaban activity measurements and the
exact time point of last DOAC intake would be valuable. Impaired
renal function could potentially lead to an accumulation of DOACs
in contrast to VKA, but creatinine was similar in both patient
groups.
A number of patients in both groups were treated with addi-
tional antiplatelet medication. Antiplatelet medications have been
shown to result in more complicated and longer hospital stays in
epistaxis patients.3 A previous study showed an increased length of
hospital stay for patients on VKA and antiplatelet medication as
compared to VKA alone.3 To our knowledge, a comparable investiga-
tion about the combination of antiplatelet therapy with DOAC ther-
apy in epistaxis patients does not yet exist. In our population, we
could not demonstrate a significant difference between the VKA and
DOAC group regarding additional antiplatelet use. Thus, differences
in outcomes observed between the two groups most likely result
from treatment with either a VKA or a DOAC, not from differences
in antiplatelet co-medication.
4.3 | Differences in outcome between patients on
the DOAC rivaroxaban compared with patients on
the VKA phenprocoumon
Fortunately, no patient died in the ED. The mortality rate during
hospital stay was not significantly different and equally low in both
groups.
The hospital admission rate was significantly lower and the
length of hospital stay significantly shorter in patients with epistaxis
under the DOAC rivaroxaban compared with VKA epistaxis patients.
The primary reason for these differences may be the much
shorter half-life of rivaroxaban compared with phenprocoumon.
Although no specific antidote for rivaroxaban is available at the
moment, stopping the DOAC leads to a rapid normalisation of
haemostasis, and therefore, treatment may be faster and early
removal of nasal packing is more likely to be successful compared to
patients on VKA. Furthermore, restarting or adjusting the therapeutic
range of VKAs is more complex than for DOACs and may thus con-
tribute to the longer hospital stay and higher admission rate in the
former group.
The difference in bleeding location may contribute as well to
the differences in outcome observed in this study. While anterior
bleedings are (i) easily accessible to the physician and (ii) usually
well treatable with local coagulation, anterior tamponade or other
conservative measures, posterior lesions are harder to reach and
posterior packs are more difficult to place and more uncomfortable
for the patient. Posterior packing is therefore likely to require
an increasing number of hospital admissions for monitoring
purposes.11,12
TABLE 2 Clinical characteristics, treatment and outcome of
patients according to type of anticoagulant (n=440)
Variables
Rivaroxaban
n=123 (28%)
Phenprocoumon
n=317 (78%) P-value
Vital signs
BPsys (mm Hg) 145.636.8 146.434.1 .838
BPdia (mm Hg) 73.124.1 80.920.2 .056
Blood results
Creatinine (lmol/l) 104.542.5 113.158.5 .665
INR 1.280.28 2.630.87 <.001*
Haemoglobin (g/L) 125.417.7 124.723.4 .826
Thrombocytes (G/L) 209.987.0 212.176.7 .883
Location of epistaxis(%)
Anterior 74 (60.2) 139 (43.8) .002*
Diffuse 1 (0.8) 16 (5.0) .050
Posterior 7 (5.7) 39 (12.3) .042*
Not documented or
not visualised in
endoscopy
41 (33.3) 123 (38.8) .287
Treatment(%)
No therapy needed 0 (0) 6 (1.9) .192
Cauterisation 39 (31.7) 86 (27.1) .339
Nasal packing 29 (23.6) 85 (26.8) .487
Cauterisation and
nasal packing
22 (17.9) 42 (13.2) .216
Surgery 0 (0) 2 (0.6) 1.000
Not documented 33 (26.8) 96 (30.3) .475
Blood transfusion
needed
2 (1.6) 3 (0.9) .622
Outcome parameter
Hospital admissions 12 (10.4%) 57 (18.0%) .033*
Length of hospital
stay (days)
0.72.2 1.53.7 .011*
ED mortality 0 (0%) 0 (0%) 1.000
In-hospital mortality 1 (0.8%) 3 (0.9%) 1.000
Mean standard deviation or percentage (%) as appropriate, independent
samples t-test, Mann-Whitney U and Pearson’s Chi-Square or Fisher’s
exact test as applicable.
INR, International normalised ratio; BPsys, systolic blood pressure; BPdia,
diastolic blood pressure; bpm, beats per minute; ED, emergency depart-
ment. *P<.05.
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4.4 | Clinical applicability of the study
Minor bleeding complications such as epistaxis are frequent in
patients under anticoagulant medication and thus pose a relevant
medical, social and economic challenge. The differences in outcome
between patients with epistaxis treated with either the DOAC
rivaroxaban or the VKA phenprocoumon have not previously been
described and should now add further weight to the evidence for
prescribing DOACs in preference over VKAs. Further research
regarding the transferability of these results to patients treated with
other VKAs like warfarin is recommended.
4.5 | Limitations
Despite a careful review of all available documentation, it is possible
that not all eligible patients were included in this study due to
potential documentation biases. However, this bias can reasonably
be expected to be evenly distributed between groups and thus
should not affect the conclusions of this study. As our hospital is a
university hospital, epistaxis patients that are treated in our ED are
most likely subject to a selection bias. This limitation should however
be the same for both anticoagulants investigated in this study as
well. Because we excluded traumatic epistaxis from our study to
avoid a too heterogeneous patient population with different mecha-
nisms of epistaxis, the role of anticoagulation in this patient group
should be subject to further research. Furthermore the different size
of groups compared with our investigation reflects the lower preva-
lence of DOACs compared to VKAs in our consecutive sample of ED
admissions.
Due to the retrospective study design, no comparison of patient
groups with different dosages of rivaroxaban and different time
points of last intake was possible, because neither of these informa-
tion is routinely documented. Future studies should address the pos-
sibility that the differences observed in this study are ascribable to
patients having a very distant intake of the last dose of DOAC com-
pared to patients on VKAs.
One key difference between both groups is that patients with
mechanical heart valves are often anticoagulated with a VKA. To
assess the suspicion that these patients might be targeted towards a
higher INR and that this may in turn explain the differences
observed in this study, we compared INR in patients with and with-
out mechanical heart valves. Failure to find a difference between
these patients may however be due to a lack of power as the group
with mechanical valves is comparatively small (only about 10% of all
patients under VKA).
The number of cases with incomplete documentation of some
parameters, owed to the retrospective study design, was not signifi-
cantly different between the compared groups and therefore should
not compromise the results. Nevertheless, further prospective stud-
ies should be conducted to confirm our results.
Inclusion of other DOACs than rivaroxaban in such a study
would be desirable. It was not possible in our analysis due to the
small number of patients on other DOAC medications admitted to
our ED. Further research should be performed in the future, includ-
ing a comparison of patients treated with different DOACs.
In our population, no standardised approach to the treatment of
epistaxis in patients with DOAC anticoagulation was used. There-
fore, we can only describe the treatment in our patients and are
unable to recommend a best therapeutic approach in epistaxis
patients under DOAC anticoagulant therapy. Further prospective
research about specific therapies of epistaxis in patients with such
anticoagulant treatment is needed.
5 | CONCLUSION
Our study suggests that epistaxis on the DOAC rivaroxaban is asso-
ciated with shorter hospital stays and less hospital admissions com-
pared to epistaxis on vitamin K antagonist phenprocoumon. The
increased number of anterior and lower number of posterior epis-
taxis in rivaroxaban compared to patients treated with phenpro-
coumon may partially contribute to this observed outcome
differences.
Further research on epistaxis on anticoagulants and specifically
on DOAC therapy as well as other VKAs like warfarin is necessary.
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